Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...
Novo Nordisk Moves to Acquire 2seventy bio’s Hemophilia A Program and Gene-Editing Technology
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading Danish biopharmaceutical company, is transitioning from a...
Hybio Pharmaceutical Gets FDA Nod for Tirzepatide Raw Materials in DMF Filing
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Abbisko Therapeutics Presents Positive Phase II Results for HCC Treatment at ESMO-GI
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of...
China’s Kingfriend Biochemical Acquires U.S.-Listed Adalimumab Biosimilar Yusimry for USD 40 Million
Nanjing Kingfriend Biochemical Pharmaceutical Co., Ltd (SHA: 603707), a Chinese pharmaceutical company, has announced the...
Shanghai Kehua Bioengineering’s Subsidiary to Acquire Remaining Stake in Technogenetics S.P.A.
Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a Chinese bioengineering company, has announced that its...
Dizal Pharmaceutical’s Golidocitinib Breaks Record with Rapid Market Launch in China
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has seen its...
GenScript Biotech Receives Over USD 410 Million in Milestone Payments for CAR-T Therapy from Janssen Biotech
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...
Jianke.com, China’s Leading Chronic Disease Management Platform, Files for Hong Kong IPO
Jianke.com, a China-based smart healthcare service platform, has filed for an initial public offering (IPO)...
TowardPi Medical Secures RMB 200 Million in Series D Financing Led by Matrix Partners
TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company, has reportedly secured RMB 200...
Amoy Diagnostics Partners with Servier to Develop Companion Diagnostic Reagent for IDH Mutations in China
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has entered into a partnership with French...
CDE Seeks Public Input on Latest Batch of Generic Chemical Reference Preparations
The Center for Drug Evaluation (CDE), a key component of China’s National Medical Products Administration...
HighTide Therapeutics Completes Enrollment for Two Phase III Trials of T2DM Drug Candidate HTD1801
HighTide Therapeutics Inc., (HKG: 2511), a biopharmaceutical company based in China, has announced the completion...
Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Nod for First-Line TNBC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Shanghai’s Phrontline Biopharma Secures Over RMB 100 Million in Pre-Series A Funding for ADC Development
Shanghai-based antibody drug conjugate (ADC) specialist Phrontline Biopharma has reportedly secured over RMB 100 million...
Antengene’s Xpovio Included in South Korea’s NHIS Reimbursement Drug List
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that South...
Bio-Thera Solutions’ BAT1806 Biosimilar Receives European Commission Approval
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Revvity and Sanyou Biopharmaceuticals Deepen Partnership to Advance Biologic Drug Development
Shanghai-based biotechnology company Revvity has entered into a comprehensive partnership with Sanyou Biopharmaceuticals Co., Ltd...
Novartis’s Scemblix STAMP Inhibitor for CML Accepted for Review by China’s NMPA
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has had its market filing for Scemblix (asciminib)...